The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project.
作者信息
Asllani Julijana, Mitsias Dimitrios, Konstantinou George, Priftanji Alfred, Hoxha Mehmet, Sinani Gerta, Christoff George, Zlatko Dimitrov, Makris Michael, Aggelidis Xenofon, Stipic Asja, Popovic-Grle Sanja, Deleanu Diana, Tomic-Spiric Vesna, Plavsic Aleksandra, Mungan Dilsad, Kosnik Mitja, Popov Todor A, Papadopoulos Nikolaos G, Calderon Moises
机构信息
University of Medicine Tirana, Tirana, Albania.
Allergy and Asthma Medical Clinic, Tirana, Albania.
出版信息
Clin Transl Allergy. 2023 Jun;13(6):e12266. doi: 10.1002/clt2.12266.
Abstract
摘要
相似文献
1
The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project.变应原免疫治疗不良事件登记处：欧洲变态反应和临床免疫学会特别工作组项目的设立与方法
Clin Transl Allergy. 2023 Jun;13(6):e12266. doi: 10.1002/clt2.12266.
2
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.变应原免疫治疗更新：美国过敏、哮喘和免疫学学会/欧洲过敏和临床免疫学学会/PRACTALL 共识报告。
J Allergy Clin Immunol. 2013 May;131(5):1288-96.e3. doi: 10.1016/j.jaci.2013.01.049. Epub 2013 Mar 14.
3
Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology.变应原免疫疗法使用指南。加拿大过敏与临床免疫学会。
CMAJ. 1995 May 1;152(9):1413-9.
4
Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.欧洲和美国变应原免疫疗法流派之间的折中：来自墨西哥免疫疗法指南制定小组（GUIMIT）的讨论
World Allergy Organ J. 2020 Aug 21;13(8):100444. doi: 10.1016/j.waojou.2020.100444. eCollection 2020 Aug.
5
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.EAACI：变应原特异性免疫治疗的欧洲宣言。设计变应原特异性免疫治疗的未来。
Clin Transl Allergy. 2012 Oct 30;2(1):20. doi: 10.1186/2045-7022-2-20.
6
One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions.过敏原免疫治疗欧洲过敏与临床免疫学会百年庆典：未解答问题的回顾。
Allergy. 2012 Apr;67(4):462-76. doi: 10.1111/j.1398-9995.2012.02785.x. Epub 2012 Feb 6.
7
[GUIMIT 2019, Mexican Guideline on Immunotherapy. Guideline on the diagnosis of IgE-mediated allergic disease and immunotherapy following the ADAPTE approach].[《2019年墨西哥免疫疗法指南：基于ADAPTE方法的IgE介导的过敏性疾病诊断及免疫疗法指南》]
Rev Alerg Mex. 2019;66 Suppl 1:1-105. doi: 10.29262/ram.v66i5.631.
8
Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report.变应原免疫疗法：来自欧洲变态反应和临床免疫学会/美国变态反应、哮喘与免疫学会/PRACTALL 共识报告的新语义框架
Allergy. 2013 Jul;68(7):825-8. doi: 10.1111/all.12180.
9
Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology.变应原免疫疗法的实践参数。实践参数联合工作组，代表美国过敏、哮喘与免疫学会、美国过敏、哮喘与免疫学院以及过敏、哮喘与免疫联合委员会。
J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1001-11.
10
Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.基于重组 B 细胞表位的草花粉疫苗 BM32 的免疫治疗的安全性和有效性。
J Allergy Clin Immunol. 2018 Aug;142(2):497-509.e9. doi: 10.1016/j.jaci.2017.09.052. Epub 2018 Jan 17.
引用本文的文献
1
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.意大利变应原免疫治疗登记处（RIAIT）：为过敏症专科医生提供疾病修饰治疗新视野下的新工具方案。
J Pers Med. 2024 Aug 12;14(8):854. doi: 10.3390/jpm14080854.
2
Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies-Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce.接受呼吸道过敏变应原免疫治疗的儿童和青少年的不良事件——来自欧洲变态反应和临床免疫学会工作组变应原免疫治疗不良事件登记处（ADER）的报告
Clin Transl Allergy. 2023 Jun;13(6):e12250. doi: 10.1002/clt2.12250.
本文引用的文献
1
Allergen immunotherapy: The growing role of observational and randomized trial "Real-World Evidence".变应原免疫治疗：观察性和随机试验“真实世界证据”的作用日益增加。
Allergy. 2021 Sep;76(9):2663-2672. doi: 10.1111/all.14773.
2
The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization.真实世界研究在呼吸医学中的重要性：呼吸有效性研究组宣言：获国际基层医疗呼吸组和世界变态反应组织认可
Eur Respir J. 2019 Sep 19;54(3). doi: 10.1183/13993003.01511-2019. Print 2019 Sep.
3
Side effects during subcutaneous immunotherapy in children with allergic diseases.变应性疾病患儿皮下免疫治疗中的不良反应。
Pediatr Allergy Immunol. 2018 May;29(3):267-274. doi: 10.1111/pai.12847. Epub 2018 Jan 17.
4
Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.5 年 SQ 豚草舌下免疫治疗片剂哮喘预防（GAP）试验结果在儿童花粉过敏症。
J Allergy Clin Immunol. 2018 Feb;141(2):529-538.e13. doi: 10.1016/j.jaci.2017.06.014. Epub 2017 Jul 6.
5
Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis.变应性鼻炎结膜炎的变应原免疫治疗：系统评价和荟萃分析。
Allergy. 2017 Nov;72(11):1597-1631. doi: 10.1111/all.13201. Epub 2017 Jul 14.
6
European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.欧洲变应原免疫治疗中全身不良反应调查（EASSI）：真实临床评估。
Allergy. 2017 Mar;72(3):462-472. doi: 10.1111/all.13066. Epub 2016 Nov 10.
7
An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology.一项 EAACI“过敏原免疫治疗中全身性不良反应的欧洲调查 (EASSI)”: 方法学。
Clin Transl Allergy. 2014 Jul 21;4:22. doi: 10.1186/2045-7022-4-22. eCollection 2014.
8
Research needs in allergy: an EAACI position paper, in collaboration with EFA.过敏研究需求：一项与 EFA 合作的 EAACI 立场文件。
Clin Transl Allergy. 2012 Nov 2;2(1):21. doi: 10.1186/2045-7022-2-21.
Zotero 插件